Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

NCT01699464 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT01699464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01699464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
April 30, 2013
Enrollment
211 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open-angle glaucoma